Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard Post History

by MirrorWorldMan


V.SBM

RE:RE:RE:Question

There is little more that can be said. The lack of facts in itself is...

July 19, 2017

V.SBM

RE:RE:RE:RE:RE:RE:RE:Valent just sold OBAGi

Sirona wants to be bought, we even have a M & A executive onboard to find...

July 18, 2017

V.SBM

RE:RE:RE:RE:Valent just sold OBAGi

Odds are better this Chinese company will shed the lower quality asset, sell...

July 18, 2017

V.SBM

RE:RE:RE:Bioalternatives skin pigmentation tests

I hope you are correct and the findings of the other meetoos are compelling...

July 17, 2017

V.SBM

RE:Bioalternatives skin pigmentation tests

Why is Sirona hiring a CRA to test their skin lighteners if Mr Verrico says a...

July 16, 2017

V.SBM

Pubah says..

There is no solid 3rd party support at Mr Verrico is negotiating anything of...

July 7, 2017

T.CF

Pubah?

There is no solid evidence that Mr Verrico is negotiating anything 

July 7, 2017

T.CF

TD price target too low

My calculations have (.25/share quarterly earnings x 4 quarters x ~9 price...

July 7, 2017

V.SBM

RE:News...

Preclinical results data out of a Petri dish is not enough.  Markets are...

July 6, 2017

V.SBM

That PP recipient must be a novice.

No trading volumes Anaemic cash flows, no guidance, constant dilutions and...

July 5, 2017

T.CXR.R

RE:RE:RE:news

...."The optimal capital structure for a company is one that...

June 21, 2017

T.CXR.R

RE:RE:news

I read an equity transaction in the near future. 

June 21, 2017

V.SBM

RE:RE:RE:Some upward pressure from Europe.

The CDA explicitly recommends EmpaG by name for diabetes patients with...

June 17, 2017

T.CXR.R

RE:WTF

Shorty covering down south 

June 17, 2017

T.CXR.R

RE:AGM

correction:... no shareholders in attendance were online chose to "ask...

June 15, 2017

T.CXR.R

AGM

I visited the website described in the AGM background document and listened...

June 15, 2017

T.CXR.R

RE:RE:SHORT THE FRACK OUT OF EVERY BUMP

if the vertically challenged cannot cover now, they never will.

June 14, 2017

V.SBM

RE:RE:RE:RE:RE:sglt1 and sglt2 dual inhibitor worked in Ph3

Receptor site specificity for SGLT may not be clinically relevant, that's...

June 14, 2017

V.SBM

RE:RE:RE:sglt1 and sglt2 dual inhibitor worked in Ph3

The 3 SGLT2's currently available have similar efficacy becaus they have...

June 13, 2017

V.SBM

RE:sglt1 and sglt2 dual inhibitor worked in Ph3

Over 90% of Glucose Transport occurs via the SGLT2 subtype, SGLT1 is minimal....

June 12, 2017

Featured Company